PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Therefore, this study did not have sufficient power to clarify whether the PNPLA3 polymorphism is an independent risk factor for NAFLD and/or a decline in the eGFR in overweight subjects, and a type 2 error cannot be excluded.